Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 81 of 1,261
  1. US 12151001

    Optimized expression cassettes for gene therapy

    Tenaya Therapeutics, Inc. Β· Granted Nov 26, 2024 Β· Expires Nov 21, 2044

    granted
  2. US 12152028

    Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated Β· Granted Nov 26, 2024 Β· Expires Nov 21, 2044

    granted
  3. US 12150998

    Bicyclic peptide ligands specific for P-selectin

    BicycleTx Limited Β· Granted Nov 26, 2024 Β· Expires Nov 21, 2044

    granted
  4. US 12151062

    Compositions and devices to administer pharmaceutical compositions nasally

    The Board of Regents of the University of Texas System Β· Granted Nov 26, 2024 Β· Expires Nov 21, 2044

    granted
  5. US 12150995

    IRAK degraders and uses thereof

    Kymera Therapeutics, Inc. Β· Granted Nov 26, 2024 Β· Expires Nov 21, 2044

    granted
  6. US 12144843

    Methods and compositions for modulating myofibroblast activities

    The Regents of the University of California Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  7. US 12144801

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  8. US 12144809

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  9. US 12146004

    Polymyxin compounds and uses thereof

    SPERO THERAPEUTICS, INC. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  10. US 12145974

    Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin

    SUNSHINE LAKE PHARMA CO., LTD. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  11. US 12146139

    Oligonucleotide interference treatments of prostate cancer

    The Board of Regents of the University of Oklahoma Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  12. US 12145973

    T-cell modulatory multimeric polypeptides and methods of use thereof

    Cue Biopharma, Inc. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  13. US 12145939

    Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators

    PRAXIS PRECISION MEDICINES, INC. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  14. US 12145941

    Heterocyclic antiviral agents

    Enanta Pharmaceuticals, Inc. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  15. US 12144881

    Cosmetic composition containing Ξ±-mangostin, method for preparation, and uses thereof

    CHINA PHARMACEUTICAL UNIVERSITY Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  16. US 12144868

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  17. US 12144864

    Tubulysins and protein-tubulysin conjugates

    REGENERON PHARMACEUTICALS, INC. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  18. US 12144890

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  19. US 12144876

    Security mechanisms for radiopharmaceutical elution system and elution process

    Jubilant Draximage Inc. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  20. US 12145922

    Selective D3 dopamine receptor agonists and methods of their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  21. US 12144867

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  22. US 12145963

    Phenothiazine derivatives and uses thereof

    CAMP4 Therapeutics Corporation Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  23. US 12144813

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted
  24. US 12144815

    Use of aprepitant for treating Alzheimer's disease

    Hoth Therapeutics, Inc. Β· Granted Nov 19, 2024 Β· Expires Nov 14, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.